• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Sue J. Goldie, MD, MPH


  • Goldie SJ, Levin C, Mosqueira-Lovón NR, Ortendahl J, Kim J, O'Shea M, Diaz Sanchez M, Mendoza Araujo MA.Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.Rev. Panam. Salud Publica. 2012 Dec;32(6):426-34.
  • Price RA, Frank RG, Cleary PD, Goldie SJ.Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests.Med Care. 2011 Feb;49(2):132-8.
  • Profit J, Lee D, Zupancic JA, Papile L, Gutierrez C, Goldie SJ, Gonzalez-Pier E, Salomon JA.Clinical benefits, costs, and cost-effectiveness of neonatal intensive care in Mexico.PLoS Med. 2010;7(12):e1000379.
  • Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ.Cost-effectiveness of human papillomavirus vaccination and screening in Spain.Eur J Cancer. 2010 Nov;46(16):2973-85.
  • Goldhaber-Fiebert JD, Stout NK, Goldie SJ.Empirically Evaluating Decision-Analytic Models.Value Health. 2010 Aug;13(5):667-74. Review.
  • Levin CE, Sellors J, Shi JF, Ma L, Qiao YL, Ortendahl J, O'Shea MK, Goldie SJ.Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China.Int J Cancer. 2010 Sep 1;127(6):1404-11.
  • Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ.Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.Cancer. 2010 Jun 15;116(12):2941-53.
  • Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L.A model-based estimate of cumulative excess mortality in survivors of childhood cancer.Ann Intern Med. 2010 Apr 6;152(7):409-17, W131-8.
  • Kim JJ, Ortendahl J, Goldie SJ.Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.Ann Intern Med. 2009 Oct 20;151(8):538-45.
  • Kim JJ, Goldie SJ.Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.BMJ. 2009;339:b3884.
  • Yeh JM, Goldie SJ, Kuntz KM, Ezzati M.Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections.Cancer Causes Control. 2009 Jul 30.
  • Wideroff L,Phillips KA,Randhawa G,Ambs A,Armstrong K,Bennett CL,Brown ML,Donaldson MS,Follen M,Goldie SJ,Hiatt RA,Khoury MJ,Lewis G,McLeod HL,Piper M,Powell I,Schrag D,Schulman KA,Scott J.A health services research agenda for cellular, molecular and genomic technologies in cancer care.Public Health Genomics. 2009;12(4):233-44. Review.
  • Goldie SJ,Diaz M,Constenla D,Alvis N,Andrus JK,Kim SY.Mathematical models of cervical cancer prevention in Latin America and the Caribbean.Vaccine. 2008 Aug 19;26 Suppl 11:L59-72.
  • Andrus JK,Lewis MJ,Goldie SJ,Garcia PJ,Winkler JL,Ruiz-Matus C,de Quadros CA.Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean.Vaccine. 2008 Aug 19;26 Suppl 11:L80-7. Review.
  • Munoz N,Franco EL,Herrero R,Andrus JK,de Quadros C,Goldie SJ,Bosch FX.Recommendations for cervical cancer prevention in Latin America and the Caribbean.Vaccine. 2008 Aug 19;26 Suppl 11:L96-L107. Review.
  • Goldie SJ,O'Shea M,Diaz M,Kim SY.Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.Reprod Health Matters. 2008 Nov;16(32):86-96.
  • Stout NK,Goldie SJ.Keeping the noise down: common random numbers for disease simulation modeling.Health Care Manag Sci. 2008 Dec;11(4):399-406.
  • Goldie SJ,Diaz M,Kim SY,Levin CE,Van Minh H,Kim JJ.Mathematical models of cervical cancer prevention in the Asia Pacific region.Vaccine. 2008 Aug 19;26 Suppl 12:M17-29.
  • Garland SM,Cuzick J,Domingo EJ,Goldie SJ,Kim YT,Konno R,Parkin DM,Qiao YL,Sankaranarayanan R,Stern PL,Tay SK,Bosch FX.Recommendations for cervical cancer prevention in Asia Pacific.Vaccine. 2008 Aug 19;26 Suppl 12:M89-98.
  • Kim JJ,Brisson M,Edmunds WJ,Goldie SJ.Modeling cervical cancer prevention in developed countries.Vaccine. 2008 Aug 19;26 Suppl 10:K76-86. Review.
  • Andersson KL,Salomon JA,Goldie SJ,Chung RT.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol. 2008 Dec;6(12):1418-24.
  • Yeh JM,Kuntz KM,Ezzati M,Goldie SJ.Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results.Int J Cancer. 2009 Jan 1;124(1):157-66.
  • Stout NK,Goldhaber-Fiebert JD,Ortendahl JD,Goldie SJ.Trade-offs in cervical cancer prevention: balancing benefits and risks.Arch Intern Med. 2008 Sep 22;168(17):1881-9.
  • Kim JJ,Goldie SJ.Health and economic implications of HPV vaccination in the United States.N Engl J Med. 2008 Aug 21;359(8):821-32.
  • Kim JJ,Kobus KE,Diaz M,O'Shea M,Van Minh H,Goldie SJ.Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.Vaccine. 2008 Jul 29;26(32):4015-24.
  • Goldie SJ,O'Shea M,Campos NG,Diaz M,Sweet S,Kim SY.Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.Vaccine. 2008 Jul 29;26(32):4080-93.
  • Hu D, Goldie S.The economic burden of noncervical human papillomavirus disease in the United States.Am J Obstet Gynecol. 2008 May;198(5):500.e1-7. Review.
  • Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.Journal of the National Cancer Institute. 2008 Mar 5;100(5):308-20.
  • Kim SY, Goldie SJ.Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.Pharmacoeconomics. 2008;26(3):191-215. Review.
  • Kim SY, Salomon JA, Goldie SJ.Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.Bull World Health Organ. 2007 Nov;85(11):833-42.
  • Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA.Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.Popul Health Metr. 2007;5:11.
  • Kim JJ, Andres-Beck B, Goldie SJ.The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.Br J Cancer. 2007 Nov 5;97(9):1322-8.
  • Kwon J, Carey M, Goldie S, Kim J.Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma.Obstet Gynecol. 2007 Oct;110(4):933; author reply 933-4.
  • Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA.The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.HIV Med. 2007 Oct;8(7):439-50.
  • Hu D, Bertozzi SM, Gakidou E, Sweet S, Goldie SJ.The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico.PLoS ONE. 2007;2(1):e750.
  • Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier Bosch F, de Sanjose S, Franco EL.Cost-effectiveness of HPV 16, 18 vaccination in Brazil.Vaccine. 2007 Aug 14;25(33):6257-70.
  • Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ.Multiparameter calibration of a natural history model of cervical cancer.Am J Epidemiol. 2007 Jul 15;166(2):137-50.
  • Agosti JM, Goldie SJ.Introducing HPV vaccine in developing countries--key challenges and issues.N Engl J Med. 2007 May 10;356(19):1908-10.
  • Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA,.HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.AIDS. 2007 May 11;21(8):973-82.
  • Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ.Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.Am J Med. 2007 Mar;120(3):272-9.
  • Kwon JS, Carey MS, Goldie SJ, Kim JJ.Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer.J Obstet Gynaecol Can. 2007 Feb;29(2):131-9.
  • Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, , Garcia F.American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors.CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28. Review.
  • Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E.Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients.J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S113-8.
  • Kim JJ, Salomon JA, Weinstein MC, Goldie SJ.Packaging health services when resources are limited: the example of a cervical cancer screening visit.PLoS Med. 2006 Nov;3(11):e434.
  • Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.N Engl J Med. 2006 Sep 14;355(11):1141-53.
  • Garnett GP, Kim JJ, French K, Goldie SJ.Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.Vaccine. 2006 Aug 21;24 Suppl 3:S178-86. Review.
  • Goldie SJ, Kim JJ, Myers E.Chapter 19: Cost-effectiveness of cervical cancer screening.Vaccine. 2006 Aug 21;24 Suppl 3:S164-70. Review.
  • Goldie SJ, Goldhaber-Fiebert JD, Garnett GP.Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling.Vaccine. 2006 Aug 21;24 Suppl 3:S155-63. Review.
  • Goldhaber-Fiebert JD, Goldie SJ.Estimating the cost of cervical cancer screening in five developing countries.Cost Eff Resour Alloc. 2006 Aug 3;4(1):13.
  • Kimmel AD, Losina E, Freedberg KA, Goldie SJ.Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries.Bull World Health Organ. 2006 Jul;84(7):581-8. Review.
  • Roux L, Kuntz KM, Donaldson C, Goldie SJ.Economic evaluation of weight loss interventions in overweight and obese women.Obesity (Silver Spring). 2006 Jun;14(6):1093-106.
  • Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA.Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire.S Afr Med J. 2006 Jun;96(6):526-9.
  • Korves CT, Goldie SJ, Murray MB.Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy.Clin Infect Dis. 2006 Aug 15;43(4):490-3.
  • Hu D, Hook EW, Goldie SJ.The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies.Sex Transm Dis. 2006 Jul;33(7):428-36.
  • Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ,.Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.
  • Korves CT, Goldie SJ, Murray MB.Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States.PLoS Med. 2006 Feb;3(2):e21.
  • Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC,.Cost-effectiveness of cervical-cancer screening in five developing countries.N Engl J Med. 2005 Nov 17;353(20):2158-68.
  • Goldhaber-Fiebert JD, Denny LE, De Souza M, Wright TC, Kuhn L, Goldie SJ.The costs of reducing loss to follow-up in South African cervical cancer screening.Cost Eff Resour Alloc. 2005 Nov 15;3:11.
  • Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA.Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Clin Infect Dis. 2005 Nov 1;41(9):1316-23.
  • Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA,.Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.AIDS. 2005 Aug 12;19(12):1299-308.
  • Aledort JE, Hook EW, Weinstein MC, Goldie SJ.The cost effectiveness of gonorrhea screening in urban emergency departments.Sex Transm Dis. 2005 Jul;32(7):425-36.
  • Kim JJ, Wright TC, Goldie SJ.Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.
  • Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP.Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.J Acquir Immune Defic Syndr. 2005 May 1;39(1):69-77.
  • Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA,.Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.Antivir Ther. 2005;10(1):41-52.
  • Hu D, Hook EW, Goldie SJ.Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.Ann Intern Med. 2004 Oct 5;141(7):501-13.
  • Salomon JA, Weinstein MC, Goldie SJ.Taking account of future technology in cost effectiveness analysis.BMJ. 2004 Sep 25;329(7468):733-6.
  • Anhang R, Goodman A, Goldie SJ.HPV communication: review of existing research and recommendations for patient education.CA Cancer J Clin. 2004 Sep-Oct;54(5):248-59.
  • Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA.A therapeutic HIV vaccine: how good is good enough?.Vaccine. 2004 Sep 28;22(29-30):4044-53.
  • Schackman BR, Oneda K, Goldie SJ.The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women.AIDS. 2004 Sep 3;18(13):1827-34.
  • Kim JJ, Leung GM, Woo PP, Goldie SJ.Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.J Public Health (Oxf). 2004 Jun;26(2):130-7.
  • Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.
  • Goldie SJ, Kim JJ, Wright TC.Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.Obstet Gynecol. 2004 Apr;103(4):619-31.
  • Anhang R, Wright TC, Smock L, Goldie SJ.Women's desired information about human papillomavirus.Cancer. 2004 Jan 15;100(2):315-20.
  • Anhang R, Stryker JE, Wright TC, Goldie SJ.News media coverage of human papillomavirus.Cancer. 2004 Jan 15;100(2):308-14.
  • Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.Int J Cancer. 2003 Oct 10;106(6):896-904.
  • Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA.Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.Antivir Ther. 2002 Dec;7(4):257-66.
  • Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA.Prevention of human immunodeficiency virus related opportunistic infections in France: A cost-effectiveness analysis.Clin Infect Dis. 2003;36(1):86-96.
  • Kuehne FC, Bethe U, Freedberg K, Goldie SJ.Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.Arch Intern Med. 2002 Dec 9-23;162(22):2545-56.
  • Goldie SJ.Health economics and cervical cancer prevention: a global perspective.Virus Res. 2002 Nov;89(2):301-9.
  • Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ.Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.Arch Intern Med. 2002 Nov 25;162(21):2478-86.
  • Corso PS, Hammitt JK, Graham JD, Dicker RC, Goldie SJ.Assessing preferences for prevention versus treatment using willingness to pay.Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S92-101.
  • Fisman DN, Lipsitch M, Hook EW, Goldie SJ.Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States.Sex Transm Dis. 2002 Oct;29(10):608-22.
  • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.Empirically calibrated model of hepatitis C virus infection in the United States.Am J Epidemiol. 2002 Oct 15;156(8):761-73.
  • Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA.Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):27-37.
  • Seage GR, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA.The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality.J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):421-8.
  • Kuntz KM, Goldie SJ.Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias.Med Decis Making. 2002 May-Jun;22(3):218-27.
  • Kim JJ, Wright TC, Goldie SJ.Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.JAMA. 2002 May 8;287(18):2382-90.
  • Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA.Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.Arch Intern Med. 2002 Apr 22;162(8):921-8.
  • Johri M, David Paltiel A, Goldie SJ, Freedberg KA.State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.Med Care. 2002 May;40(5):429-41.
  • Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC.Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.Med Decis Making. 2002 Jan-Feb;22(1):27-38.
  • Zanetti G, Goldie SJ, Platt R.Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery.Emerg Infect Dis. 2001 Sep-Oct;7(5):820-7.
  • Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA.Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.Am J Public Health. 2001 Sep;91(9):1456-63.
  • Yazdanpanah Y, Chêne G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA.Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.Int J Epidemiol. 2001 Aug;30(4):864-71.
  • Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.Am J Med. 2001 Aug;111(2):140-9.
  • Wittenberg E, Goldie SJ, Graham JD.Predictors of hazardous child seating behavior in fatal motor vehicle crashes: 1990 to 1998.Pediatrics. 2001 Aug;108(2):438-42.
  • Hagen MD, Garber AM, Goldie SJ, Lafata JE, Mandelblatt J, Meltzer D, Neumann P, Siegel JE, Sox HC, Tsevat J.Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium.Med Decis Making. 2001 Jul-Aug;21(4):307-23.
  • Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC.Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.JAMA. 2001 Jun 27;285(24):3107-15.
  • Shireman TI, Tsevat J, Goldie SJ.Time costs associated with cervical cancer screening.Int J Technol Assess Health Care. 2001 Winter;17(1):146-52.
  • Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA.Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Ann Intern Med. 2001 Mar 20;134(6):440-50.
  • Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ.The cost effectiveness of combination antiretroviral therapy for HIV disease.N Engl J Med. 2001 Mar 15;344(11):824-31.
  • Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA.Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.Clin Infect Dis. 2001 Mar 1;32(5):783-93.
  • Wright TC, Goldie SJ, Cain JM, Howett MK.Screening for cervical cancer.Science. 2000 Dec 1;290(5497):1651.
  • Fisman DN, Reilly DT, Karchmer AW, Goldie SJ.Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly.Clin Infect Dis. 2001 Feb 1;32(3):419-30.
  • Neumann PJ, Goldie SJ, Weinstein MC.Preference-based measures in economic evaluation in health care.Annu Rev Public Health. 2000;21:587-611.
  • Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ.Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.Am J Prev Med. 2000 Jul;19(1):15-23.
  • Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM.Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.Am J Med. 2000 Jun 1;108(8):634-41.
  • Mrus JM, Goldie SJ, Weinstein MC, Tsevat J.The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy.AIDS. 2000 Nov 10;14(16):2543-52.
  • Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM.The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.JAMA. 1999 May 19;281(19):1822-9.
  • Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.Ann Intern Med. 1999 Jan 19;130(2):97-107.
  • Graham JD, Goldie SJ, Segui-Gomez M, Thompson KM, Nelson T, Glass R, Simpson A, Woerner LG.Reducing risks to children in vehicles with passenger airbags.Pediatrics. 1998 Jul;102(1):e3.
  • Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA.A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S93-105.
  • Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC.The cost-effectiveness of air bags by seating position.JAMA. 1997 Nov 5;278(17):1418-25.
  • Waxman AB, Goldie SJ, Brett-Smith H, Matthay RA.Cytomegalovirus as a primary pulmonary pathogen in AIDS.Chest. 1997 Jan;111(1):128-34.
  • Troidle L, Kliger AS, Goldie SJ, Gorban-Brennan N, Brown E, Fikrig M, Finkelstein FO.Continuous peritoneal dialysis-associated peritonitis of nosocomial origin.Perit Dial Int. 1996 Sep-Oct;16(5):505-10.
  • Goldie SJ, Kiernan-Tridle L, Torres C, Gorban-Brennan N, Dunne D, Kliger AS, Finkelstein FO.Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes.Am J Kidney Dis. 1996 Jul;28(1):86-91.